Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin's Lymphoma

被引：0

作者：

Fowler, Nathan H. ^{[1
]}

Kahanic, Stephen P. ^{[2
]}

Forero, Andres ^{[3
]}

Munteanu, Mihaela C. ^{[4
]}

Davis, Glen L. ^{[4
]}

Brown, Peter ^{[4
]}

Van Den Neste, Eric ^{[5
]}

Offner, Fritz C. ^{[6
]}

Bron, Dominique ^{[7
]}

Czuczman, Myron S. ^{[8
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Siouxland Hematol Oncol, Sioux City, IA USA

[3] Univ Alabama, Birmingham, AL USA

[4] Cephalon Inc, Frazer, PA USA

[5] Clin Univ UCL St Luc, Brussels, Belgium

[6] Univ Hosp Ghent, Ghent, Belgium

[7] Inst Jules Bordet, B-1000 Brussels, Belgium

[8] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

来源：

BLOOD | 2011年 / 118卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：353 / 353

页数：1

共 50 条

[31] Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study
Graf, Solomon A.
Cassaday, Ryan D.
Morris, Karolyn K.
Behnia, Sanaz
Wu, Qian Vicky
Voutsinas, Jenna M.
Lynch, Ryan C.
Krakow, Elizabeth
Rasmussen, Heather A.
Chauncey, Thomas R.
Kanan, Sandra
Soma, Lorinda A.
Smith, Stephen D.
Gopal, Ajay K.
BLOOD, 2019, 134
[32] A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Ogura, Michinori
Ando, Kiyoshi
Suzuki, Tatsuya
Ishizawa, Kenichi
Oh, Sung Yong
Itoh, Kuniaki
Yamamoto, Kazuhito
Au, Wing Yan
Tien, Hwei-Fang
Matsuno, Yoshihiro
Terauchi, Takashi
Yamamoto, Keiko
Mori, Masahiko
Tanaka, Yoshinobu
Shimamoto, Takashi
Tobinai, Kensei
Kim, Won Seog
BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (06) : 768 - 776
[33] A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma
Torka, Pallawi
Patel, Priyank
Tan, Wei
Wilding, Gregory
Bhat, Seema A.
Czuczman, Myron S.
Lee, Kelvin P.
Deeb, George
Neppalli, Vishala
Mavis, Cory
Wallace, Paul
Hernandez-Ilizaliturri, Francisco J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (01): : E51 - E60
[34] Bendamustine and Rituximab Combination In Untreated Indolent Non Follicular B-Cell Non-Hodgkin's Lymphomas. A Phase II Study From The Fondazione Italiana Linfomi (INFL09)
Luminari, Stefano
Goldaniga, Maria Cecilia
Cesaretti, Marina
Orsucci, Lorella
Tucci, Alessandra
Pulsoni, Alessandro
Salvi, Flavia
Carella, Angelo Michele
Tedeschi, Alessandra
Pinto, Antonio
Stelitano, Caterina
Vallisa, Daniele
Ilariucci, Fiorella
Spina, Michele
Arcaini, Luca
Marcheselli, Luigi
Federico, Massimo
Baldini, Luca
BLOOD, 2013, 122 (21)
[35] A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study
Kimihiro Matsumoto
Nobuyuki Takayama
Yoshinobu Aisa
Hironori Ueno
Masao Hagihara
Kentaro Watanabe
Aya Nakaya
Kenko Chen
Takayuki Shimizu
Yuiko Tsukada
Yuji Yamada
Tomonori Nakazato
Akaru Ishida
Yoshitaka Miyakawa
Kenji Yokoyama
Hideaki Nakajima
Yoshihiro Masuda
Takahiro Yano
Shinichiro Okamoto
International Journal of Hematology, 2015, 101 : 554 - 562
[36] A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study
Matsumoto, Kimihiro
Takayama, Nobuyuki
Aisa, Yoshinobu
Ueno, Hironori
Hagihara, Masao
Watanabe, Kentaro
Nakaya, Aya
Chen, Kenko
Shimizu, Takayuki
Tsukada, Yuiko
Yamada, Yuji
Nakazato, Tomonori
Ishida, Akaru
Miyakawa, Yoshitaka
Yokoyama, Kenji
Nakajima, Hideaki
Masuda, Yoshihiro
Yano, Takahiro
Okamoto, Shinichiro
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 554 - 562
[37] A PHASE III STUDY OF OFATUMUMAB VS RITUXIMAB IN INDOLENT B-CELL NON-HODGKIN LYMPHOMA RELAPSED AFTER RITUXIMAB CONTAINING THERAPY (HOMER): RESULTS OF THE INTERIM ANALYSIS
Maloney, D. G.
Fukuhara, N.
Ogura, M.
Larouche, J. F.
Tournilhac, O.
Coleman, M.
Hong, X.
Fennessy, M.
Cota, M.
Woessner, M.
Tobinai, K.
HAEMATOLOGICA, 2016, 101 : 102 - 102
[38] Efficacy and Safety of Ofatumumab and Bendamustine Followed By Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma after Prior Rituximab
Kolibaba, Kathryn S.
Shtivelband, Mikhail
Kingsley, Edwin C.
Moezi, Mehdi M.
Richards, Donald
Sharman, Jeffrey P.
Feng Xiaoshu
Cannan, Megan
Fellague-Chebra, Rafik
Lyons, Roger M.
BLOOD, 2017, 130
[39] A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan
Kenichi Ishizawa
Masahiro Yokoyama
Harumi Kato
Kazuhito Yamamoto
Masanori Makita
Kiyoshi Ando
Yasunori Ueda
Yoshimichi Tachikawa
Youko Suehiro
Mitsutoshi Kurosawa
Yoshihiro Kameoka
Hirokazu Nagai
Nobuhiko Uoshima
Takayuki Ishikawa
Michihiro Hidaka
Yoshikiyo Ito
Atae Utsunomiya
Koji Fukushima
Michinori Ogura
Cancer Chemotherapy and Pharmacology, 2022, 90 : 83 - 95
[40] A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan
Ishizawa, Kenichi
Yokoyama, Masahiro
Kato, Harumi
Yamamoto, Kazuhito
Makita, Masanori
Ando, Kiyoshi
Ueda, Yasunori
Tachikawa, Yoshimichi
Suehiro, Youko
Kurosawa, Mitsutoshi
Kameoka, Yoshihiro
Nagai, Hirokazu
Uoshima, Nobuhiko
Ishikawa, Takayuki
Hidaka, Michihiro
Ito, Yoshikiyo
Utsunomiya, Atae
Fukushima, Koji
Ogura, Michinori
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 90 (01) : 83 - 95

← 1 2 3 4 5 →